|
Zanidatamab Clinical Trials
12 actively recruiting trials across 6 locations
Also known as: JZP598, ZIIHERA®, ZW25, Ziihera, zani
Pipeline
Phase 1: 1Phase 2: 7Phase 3: 3Phase 1/2: 1
Top Sponsors
- Jazz Pharmaceuticals4
- UNICANCER2
- QuantumLeap Healthcare Collaborative2
- M.D. Anderson Cancer Center1
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1
Indications
- Cancer12
- Breast Cancer7
- HER2-positive Breast Cancer3
- HER-2 Protein Overexpression2
- Metastatic Breast Cancer2
Other4 trials
Birmingham, Alabama2 trials
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
University of Alabama at Birmingham
Phase 2
PRE-I-SPY Phase I/Ib Oncology Platform Program
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
Phase 1
Phoenix, Arizona2 trials
Prescott, Arizona1 trial
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Arizona Oncology Associates, PC - NAHOA
Phase 2
Duarte, California1 trial
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
City of Hope(City of Hope National Medical Center, City of Hope Medical Center)
Phase 3
Long Beach, California1 trial
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.